Bio Rad Laboratories Stock Performance
| BIO Stock | USD 300.41 0.04 0.01% |
The firm shows a Beta (market volatility) of 1.8, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Rad will likely underperform. Bio Rad Laboratories has an expected return of -3.0E-4%. Please make sure to confirm Bio Rad Laboratories value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Bio Rad Laboratories performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bio Rad Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Bio Rad is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.01) | Five Day Return (9.08) | Year To Date Return (8.41) | Ten Year Return 150.63 | All Time Return 11.7 K |
Last Split Factor 2:1 | Last Split Date 2002-03-08 |
1 | Global Epigenetics Market 2024-2030 Market Poised for Unprecedented Growth, Topping 4.41 Bn by 2030 | 02/12/2024 |
2 | Bio-Rad to Participate in Fireside Chat During Citis 2024 Unplugged Medtech and Life Sciences Access Day | 02/22/2024 |
3 | Bio-Rad Laboratories, Inc. Shares Purchased by Sei Investments Co. | 03/07/2024 |
4 | PIVOT BIO CELEBRATED FOR SUSTAINABILITY AND INNOVATION | 03/19/2024 |
5 | Global Covid-19 Diagnostic Market Research 2024 Revised Outlook on Covid-19 Diagnostics in Response to New Variants and Shifting Market Dynamics | 03/21/2024 |
6 | MIRUS BIO NAMED A TOP WORKPLACE BY THE WISCONSIN STATE JOURNAL | 03/26/2024 |
7 | Global Cell Lysis Market Experiences Robust Growth, Expected to Achieve a CAGR of 6.79 percent Through 2028 | 03/28/2024 |
8 | Gene Expression Analysis Market is Expected to Reach 6.2 billion MarketsandMarkets | 04/03/2024 |
9 | Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | 04/04/2024 |
10 | Bio-Rads chief operating officer Andrew Last to retire | 04/10/2024 |
11 | Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay | 04/11/2024 |
12 | Acquisition by Michael Crowley of 520 shares of Bio Rad subject to Rule 16b-3 | 04/12/2024 |
| Begin Period Cash Flow | 434.2 M |
Bio |
Bio Rad Relative Risk vs. Return Landscape
If you would invest 30,412 in Bio Rad Laboratories on January 17, 2024 and sell it today you would lose (371.00) from holding Bio Rad Laboratories or give up 1.22% of portfolio value over 90 days. Bio Rad Laboratories is generating negative expected returns assuming volatility of 1.9708% on return distribution over 90 days investment horizon. In other words, 17% of stocks are less volatile than Bio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bio Rad Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Rad's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Rad Laboratories, and traders can use it to determine the average amount a Bio Rad's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -2.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIO |
Estimated Market Risk
| 1.97 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bio Rad is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Rad by adding Bio Rad to a well-diversified portfolio.
Bio Rad Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Rad, and Bio Rad fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0177 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 8.37 B | ||||
| Shares Outstanding | 23.42 M | ||||
| Price To Earning | 2.90 X | ||||
| Price To Book | 0.98 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 2.67 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 576.2 M | ||||
| Net Income | (637.32 M) | ||||
| Cash And Equivalents | 434.21 M | ||||
| Cash Per Share | 62.03 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.50 X | ||||
| Book Value Per Share | 306.51 X | ||||
| Cash Flow From Operations | 374.94 M | ||||
| Earnings Per Share | (21.81) X | ||||
| Market Capitalization | 8.76 B | ||||
| Total Asset | 12.3 B | ||||
| Retained Earnings | 9.26 B | ||||
| Working Capital | 2.53 B | ||||
| Current Asset | 466.61 M | ||||
| Current Liabilities | 208.93 M | ||||
About Bio Rad Performance
To evaluate Bio Rad Laboratories Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bio Rad generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bio Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bio Rad Laboratories market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Bio's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 229.76 | 148.82 | |
| Return On Tangible Assets | (0.06) | (0.05) | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about Bio Rad Laboratories performance evaluation
Checking the ongoing alerts about Bio Rad for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Rad Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 2.67 B. Reported Net Loss for the year was (637.32 M) with profit before taxes, overhead, and interest of 1.57 B. | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay |
- Analyzing Bio Rad's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Rad's stock is overvalued or undervalued compared to its peers.
- Examining Bio Rad's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Rad's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Rad's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Rad's stock. These opinions can provide insight into Bio Rad's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Bio Stock analysis
When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.56) | Earnings Share (21.81) | Revenue Per Share 91.453 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0177 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.